Purpose of Review <p>Individuals with chronic kidney disease (CKD) receiving haemodialysis (HD) experience increased oxidative stress and systemic inflammation, resulting in cardiovascular issues and diminished quality of life. This review seeks to evaluate the possible function of flavonoids—a varied group of plant-derived polyphenols—as supplementary therapeutic agents in HD. The review examines their antioxidant, anti-inflammatory, and endothelial-protective properties, emphasizing safety, efficacy, and therapeutic significance.</p> Recent Findings <p>Preclinical studies indicate that flavonoids reduce oxidative damage and inflammatory responses in models of renal injury. Recent clinical trials indicate enhancements in oxidative stress biomarkers, vascular function, and inflammatory parameters in dialysis patients administered flavonoid-based supplementation. Nevertheless, challenges including inadequate bioavailability, possible drug interactions, and insufficient data about long-term safety in persons with renal impairment persist as significant concerns. Moreover, discrepancies in supplement formulation and administration regimens impede translational findings.</p> Summary <p> Flavonoids demonstrate potential as safe, natural supplements to enhance clinical outcomes in HD when properly prepared and monitored. Future research must emphasize standardized dose, long-term safety assessments, and the incorporation of flavonoids into individualized renal feeding programs according to patient-specific metabolic and inflammatory profiles.</p>